Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on cancer immunotherapy that entered public markets through a business combination with Brookline Capital Acquisition Corp, a blank-check vehicle sponsored by Brookline Capital Markets, LLC that completed its IPO in 2021. The company's pipeline was anchored by antibody-based oncology candidates, including its CD40 agonist program targeting cancer immunotherapy. The March 18, 2022 8-K filing reflects activity in the period surrounding the de-SPAC closing. Following clinical setbacks in its lead program, Apexigen ceased operations in 2023. Investors and analysts seeking the full filing record and deal history for APGN can sign up for complete data at SpacDesk.